论文部分内容阅读
目的:了解武汉地区2008～2010年口服抗糖尿病药(0ADs)使用情况及变化趋势。方法:采用用药金额排序法和限定日剂量法对武汉地区24家医院2008～2010年口服抗糖尿病药使用情况进行统计分析。结果:2008～2010年武汉地区口服抗糖尿病药总用药金额和用药频度逐年上升。销售金额排序前3位的是阿卡波糖、瑞格列奈和二甲双胍,其3年销售金额之和所占比例达61.80%;而用药频度(DDDs)排序前4位的是格列齐特、阿卡波糖、格列美脲和二甲双胍,其3年DDDs之和所占比例达63.79%。格列美脲、格列齐特以及二甲双胍的日均费用(DDC)较低,2010年分别为2.08、2.35和3.42元/d。结论:武汉地区医院口服抗糖尿病药用药结构较为合理、稳定。阿卡波糖和二甲双胍最为临床认可,而格列齐特等磺脲类药物因其较好的性价比仍占重要地位。
Objective: To understand the use of oral antidiabetic drugs (0ADs) and their changing trend in Wuhan from 2008 to 2010. Methods: The order of the amount of medication and the daily dose limit method were used to analyze the use of oral antidiabetic drugs in 24 hospitals in Wuhan from 2008 to 2010. Results: From 2008 to 2010, the total amount of oral antidiabetic drugs and frequency of medication in Wuhan increased year by year. The top 3 sales were acarbose, repaglinide and metformin, which accounted for 61.80% of the sum of their sales for 3 years. The first 4 digits of DDDs were Glico Special, acarbose, glimepiride and metformin, the sum of 3-year DDDs accounted for 63.79%. The daily average cost (DDC) of glimepiride, gliclazide and metformin was lower at 2.08, 2.35 and 3.42 yuan / d in 2010 respectively. Conclusion: The oral antidiabetic medicine in Wuhan district hospitals is reasonable and stable. Acarbose and metformin are the most clinically recognized, and sulfonylureas such as gliclazide still occupy an important position due to their better cost-effectiveness.